Karl Y Hostetler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2948024/publications.pdf

Version: 2024-02-01

81434 107981 5,416 132 41 68 citations h-index g-index papers 138 138 138 2612 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs. Antimicrobial Agents and Chemotherapy, 2021, 65, e0115521.	1.4	43
2	Broad-Spectrum <i>In Vitro</i> Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524). Microbiology Spectrum, 2021, 9, e0153721.	1.2	19
3	Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate. Antiviral Research, 2019, 171, 104614.	1.9	3
4	Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. Antiviral Research, 2018, 150, 164-173.	1.9	8
5	Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia. Chemotherapy, 2018, 63, 225-237.	0.8	2
6	Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro. Antiviral Research, 2018, 158, 122-126.	1.9	5
7	A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation. Drug Delivery, 2017, 24, 1703-1712.	2.5	4
8	Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification. Journal of Medicinal Chemistry, 2016, 59, 10470-10478.	2.9	16
9	Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 271-279.	2.0	20
10	Novel mutations in the gene encoding very longâ€chain acylâ€CoA dehydrogenase identified in patients with partial carnitine palmitoyltransferase ii deficiency. Muscle and Nerve, 2013, 47, 224-229.	1.0	28
11	ODE-Adefovir As Potential Therapeutic Agent In AML. Blood, 2013, 122, 3970-3970.	0.6	0
12	A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy. Molecular Vision, 2012, 18, 1907-17.	1.1	12
13	Solution Structure of a DNA Duplex Containing the Potent Anti-Poxvirus Agent Cidofovir. Journal of the American Chemical Society, 2011, 133, 2264-2274.	6.6	25
14	Application of kinase bypass strategies to nucleoside antivirals. Antiviral Research, 2011, 92, 277-291.	1.9	39
15	Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. Bioorganic and Medicinal Chemistry, 2011, 19, 2950-2958.	1.4	19
16	Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: Inhibitors of hepatitis C virus and HIV-1 replication. Bioorganic and Medicinal Chemistry, 2011, 19, 4616-4625.	1.4	16
17	Intraocular Pharmacokinetics of a Crystalline Lipid Prodrug, Octadecyloxyethyl-Cyclic-Cidofovir, for Cytomegalovirus Retinitis. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 157-162.	0.6	7
18	Intraocular Safety and Pharmacokinetics of Hexadecyloxypropyl-Cidofovir (HDP-CDV) as a Long-lasting Intravitreal Antiviral Drug., 2011, 52, 9391.		13

#	Article	IF	CITATIONS
19	Inhibition of HIV-1 by Octadecyloxyethyl Esters of (<i>S</i>)-[3-Hydroxy-2-(Phosphonomethoxy)Propyl] Nucleosides and Evaluation of Their Mechanism of Action. Antimicrobial Agents and Chemotherapy, 2011, 55, 5063-5072.	1.4	12
20	Oral Hexadecyloxypropyl-Cidofovir Therapy in Pregnant Guinea Pigs Improves Outcome in the Congenital Model of Cytomegalovirus Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 35-41.	1.4	21
21	Antiproliferative property of hexadecyloxypropyl 9-[2-(phosphonomethoxy) ethyl] guanine (HDP-PMEG) for unwanted ocular proliferation. Molecular Vision, 2011, 17, 627-37.	1.1	9
22	Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate. Viruses, 2010, 2, 2213-2225.	1.5	65
23	Intravitreal Crystalline Drug Delivery for Intraocular Proliferation Diseases. , 2010, 51, 474.		28
24	Antiproliferative Effects of Octadecyloxyethyl 9-[2-(Phosphonomethoxy)Ethyl]Guanine against Me-180 Human Cervical Cancer Cells in vitro and in vivo. Chemotherapy, 2010, 56, 54-59.	0.8	4
25	Alkoxyalkyl Esters of 9-(<i>S</i>)-(3-Hydroxy-2-Phosphonomethoxypropyl) Adenine Are Potent and Selective Inhibitors of Hepatitis B Virus (HBV) Replication In Vitro and in HBV Transgenic Mice In Vivo. Antimicrobial Agents and Chemotherapy, 2009, 53, 2865-2870.	1.4	11
26	Antischistosomal Activity of Hexadecyloxypropyl Cyclic 9-(<i>>S</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 472 T Phosphonates Assessed by Schistosome Worm Killing In Vitro. Antimicrobial Agents and Chemotherapy, 2009, 53, 5284-5287.	d ()-[3-Hy 1.4	rdroxy-2-(Phos 16
27	The Octadecyloxyethyl Ester of (<i>S</i>)-9-[3-Hydroxy-2-(Phosphonomethoxy) Propyl]Adenine Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication in Genotype 1A, 1B, and 2A Replicons. Antimicrobial Agents and Chemotherapy, 2009, 53, 2660-2662.	1.4	38
28	Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Research, 2009, 82, A84-A98.	1.9	208
29	Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses. Antiviral Research, 2009, 84, 254-259.	1.9	17
30	Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. Antiviral Research, 2008, 79, 133-135.	1.9	18
31	Inhibition of Herpesvirus Replication by Hexadecyloxypropyl Esters of Purine- and Pyrimidine-Based Phosphonomethoxyethyl Nucleoside Phosphonates. Antimicrobial Agents and Chemotherapy, 2008, 52, 4326-4330.	1.4	15
32	Anti-BK Virus Activity of Nucleoside Analogs. Antimicrobial Agents and Chemotherapy, 2008, 52, 1519-1521.	1.4	12
33	Cidofovir and (<i>S</i>)-9-[3-Hydroxy-(2-Phosphonomethoxy)Propyl]Adenine Are Highly Effective Inhibitors of Vaccinia Virus DNA Polymerase When Incorporated into the Template Strand. Antimicrobial Agents and Chemotherapy, 2008, 52, 586-597.	1.4	79
34	Antiviral Activities of Novel 5-Phosphono-Pent-2-en-1-yl Nucleosides and Their Alkoxyalkyl Phosphonoesters. Antimicrobial Agents and Chemotherapy, 2007, 51, 611-615.	1.4	18
35	Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates. Advances in Antiviral Drug Design, 2007, , 167-184.	0.7	6
36	Evaluation of Hexadecyloxypropyl-9- $\langle i \rangle R \langle i \rangle$ -[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 4538-4538.	1.4	3

3

#	Article	IF	CITATIONS
37	Effect of Oral Treatment with Hexadecyloxypropyl-[(S)-9-(3-Hydroxy-2-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	f 50 747 1 1.4	Td (Phospho 34
	Vaccinia Virus Infections in Mice. Antimicrobial Agents and Chemotherapy, 2007, 51, 3940-3947.		
38	Evaluation of Hexadecyloxypropyl-9- $\langle i \rangle R \langle i \rangle$ -[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 3505-3509.	1.4	68
39	Intraocular Properties of An Alkoxyalkyl Derivative of Cyclic 9-(S)-(3-Hydroxyl-2-Phosphonomehoxypropyl) Adenine, An Intravitreally Injectable Anti-HCMV Drug in Rabbit and Guinea Pig. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 433-444.	0.6	10
40	Synthesis of the 5-phosphono-pent-2-en-1-yl nucleosides: A new class of antiviral acyclic nucleoside phosphonates. Bioorganic and Medicinal Chemistry, 2007, 15, 1771-1779.	1.4	23
41	Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovirâ [†] . Antiviral Research, 2007, 75, 87-90.	1.9	20
42	Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Research, 2007, 73, 212-218.	1.9	31
43	In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antiviral Research, 2007, 75, 52-57.	1.9	37
44	Synthesis and Antiviral Evaluation of Alkoxyalkyl Derivatives of 9-(S)-(3-Hydroxy-2-phosphonomethoxypropyl)adenine against Cytomegalovirus and Orthopoxviruses. Journal of Medicinal Chemistry, 2006, 49, 2010-2015.	2.9	73
45	Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro. Antiviral Research, 2006, 72, 10-19.	1.9	32
	Activities of Alkoxyalkyl Esters of Cidofovir (CDV), Cyclic CDV, and (S) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387	Td ()-9-(3-	Hydroxy-2-P
46	in Organotypic Cultures. Antimicrobial Agents and Chemotherapy, 2006, 50, 2525-2529.	1.4	39
47	Synthesis and Antiviral Evaluation of Alkoxyalkyl Esters of Phosphonopropoxymethyl-Guanine and Phosphonopropoxymethyl-Diaminopurine. Antiviral Chemistry and Chemotherapy, 2006, 17, 89-95.	0.3	11
48	Alkoxyalkyl Esters of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy)Propyl]Adenine Are Potent Inhibitors of the Replication of Wild-Type and Drug-Resistant Human Immunodeficiency Virus Type 1 In Vitro. Antimicrobial Agents and Chemotherapy, 2006, 50, 2857-2859.	1.4	30
49	Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Molecular Cancer Therapeutics, 2006, 5, 156-159.	1.9	20
50	Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR Are Associated with the Drug Resistance Phenotype. Antimicrobial Agents and Chemotherapy, 2006, 50, 4038-4043.	1.4	50
51	Ether Lipid Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2006, 50, 1564-1566.	1.4	75
52	Characterization and Treatment of Cidofovir-Resistant Vaccinia (WR Strain) Virus Infections in Cell Culture and in Mice. Antiviral Chemistry and Chemotherapy, 2005, 16, 203-211.	0.3	24
53	Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate. Antimicrobial Agents and Chemotherapy, 2005, 49, 3153-3162.	1.4	128
54	Intraocular Properties of Hexadecyloxypropyl–Cyclic-Cidofovir in Guinea Pigs. Journal of Ocular Pharmacology and Therapeutics, 2005, 21, 205-209.	0.6	8

#	Article	IF	CITATIONS
55	Comparison of the Antiviral Activities of Alkoxyalkyl and Alkyl Esters of Cidofovir against Human and Murine Cytomegalovirus Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2005, 49, 656-662.	1.4	76
56	Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro. Antimicrobial Agents and Chemotherapy, 2005, 49, 3724-3733.	1.4	136
57	Ether Lipidâ€Ester Prodrugs of Acyclic Nucleoside Phosphonates: Activity against Adenovirus Replication In Vitro. Journal of Infectious Diseases, 2005, 191, 396-399.	1.9	121
58	Characterization of a Novel Intraocular Drug-Delivery System Using Crystalline Lipid Antiviral Prodrugs of Ganciclovir and Cyclic Cidofovir., 2004, 45, 4138.		42
59	Oral Activity of Ether Lipid Ester Prodrugs of Cidofovir against Experimental Human Cytomegalovirus Infection. Journal of Infectious Diseases, 2004, 190, 499-503.	1.9	81
60	Inhibitory Activity of Alkoxyalkyl and Alkyl Esters of Cidofovir and Cyclic Cidofovir against Orthopoxvirus Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2004, 48, 1869-1871.	1.4	67
61	Oral Treatment of Cowpox and Vaccinia Virus Infections in Mice with Ether Lipid Esters of Cidofovir. Antimicrobial Agents and Chemotherapy, 2004, 48, 404-412.	1.4	152
62	Oral Treatment of Murine Cytomegalovirus Infections with Ether Lipid Esters of Cidofovir. Antimicrobial Agents and Chemotherapy, 2004, 48, 3516-3522.	1.4	66
63	Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends in Biotechnology, 2004, 22, 423-427.	4.9	82
64	Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology, 2004, 318, 474-481.	1.1	131
65	Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. International Journal of Antimicrobial Agents, 2004, 23, 430-437.	1.1	50
66	Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Research, 2003, 59, 163-171.	1.9	177
67	Increased Antiviral Activity of 1 -O-Hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 Human Lung Fibroblasts Is Explained by Unique Cellular Uptake and Metabolism. Molecular Pharmacology, 2003, 63, 678-681.	1.0	127
68	Ganciclovir Release Rates in Vitreous from Different Formulations of 1-O-Hexadecylpropanediol-3-Phospho-Ganciclovir. Journal of Ocular Pharmacology and Therapeutics, 2003, 19, 161-169.	0.6	8
69	Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2002, 46, 2381-2386.	1.4	170
70	Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir. Antimicrobial Agents and Chemotherapy, 2002, 46, 991-995.	1.4	194
71	Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Investigative Ophthalmology and Visual Science, 2002, 43, 515-21.	3.3	21
72	Alkylglycerol Prodrugs of Phosphonoformate Are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations That Suppress Zidovudine Resistance. Antimicrobial Agents and Chemotherapy, 2001, 45, 1621-1628.	1.4	45

#	Article	IF	CITATIONS
73	<i>In vitro</i> and <i>in vivo</i> Activity of 1-O-Hexadecylpropane-Diol-3-Phospho-Ganciclovir and 1-O-Hexadecylpropanediol-3-Phospho-Penciclovir in Cytomegalovirus and Herpes Simplex Virus Infections. Antiviral Chemistry and Chemotherapy, 2001, 12, 61-70.	0.3	30
74	Efficacy of Topical Acyclovir Monophosphate, Acyclovir, or Penciclovir in Orofacial HSV-1 Infections of Mice and Genital HSV-2 Infections of Guinea Pigs. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 501-513.	0.4	7
75	<i>In vitro</i> Anti-HIV-1 Activity of <i>sn</i> -2-Substituted 1-O-Octadecyl- <i>sn</i> -Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine. Antiviral Chemistry and Chemotherapy, 2000, 11, 213-219.	0.3	9
76	Antiviral Activities of Oral 1- O -Hexadecylpropanediol-3-Phosphoacyclovir and Acyclovir in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrobial Agents and Chemotherapy, 2000, 44, 1964-1969.	1.4	49
77	Synthesis and Antiviral Evaluation of 1-O-Hexadecylpropanediol-3-P-acyclovir: Efficacy Against HSV-1 Infection in Mice. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 471-479.	0.4	18
78	Intravitreal Toxicology and Therapeutic Efficacy of the Carboxymethyl Ester of the l- <i>O</i> O-Ctadecyl- <i>sn</i> -Glycerol-3-Phosphonoformate (ODG-PFA-O-Me), a Novel Lipid Antiviral Prodrug for Intraocular Drug Delivery. Journal of Ocular Pharmacology and Therapeutics, 1999, 15, 363-377.	0.6	3
79	Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA). Current Eye Research, 1999, 18, 161-167.	0.7	15
80	TREATMENT OF HERPES RETINITIS IN AN ANIMAL MODEL WITH A SUSTAINED DELIVERY ANTIVIRAL DRUG, LIPOSOMAL 1-O-OCTADECYL-SN-GLYCEROL-3-PHOSPHONOFORMATE. Retina, 1999, 19, 325.	1.0	7
81	Synthesis and in Vitro Activity of Long-Chain 5â€~-O-[(Alkoxycarbonyl)phosphinyl]-3â€~-azido-3â€~-deoxythymidines against Wild-Type and AZT- and Foscarnet-Resistant Strains of HIV-1. Journal of Medicinal Chemistry, 1997, 40, 2482-2490.	2.9	23
82	Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis b virus infection, in vitro. Biochemical Pharmacology, 1997, 53, 1815-1822.	2.0	49
83	Cardiolipin synthase from mammalian mitochondria. Lipids and Lipid Metabolism, 1997, 1348, 207-213.	2.6	72
84	Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. Antiviral Research, 1997, 36, 43-53.	1.9	23
85	EVALUATION OF A NOVEL LIPID PRODRUG FOR INTRAOCULAR DRUG DELIVERY. Retina, 1997, 17, 57-64.	1.0	15
86	Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Antiviral Research, 1996, 31, 59-67.	1.9	32
87	Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Toxicology, 1996, 106, 139-147.	2.0	36
88	Phospholipid prodrug inhibitors of the HIV protease. Biochemical Pharmacology, 1994, 48, 1399-1404.	2.0	10
89	Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antiviral Research, 1994, 24, 59-67.	1.9	22
90	Mitochondrial cardiolipin in diverse eukaryotes. Comparison of biosynthetic reactions and molecular acyl species. FEBS Journal, 1993, 212, 727-733.	0.2	161

#	Article	IF	CITATIONS
91	[39] Mammalian cardiolipin biosynthesis. Methods in Enzymology, 1992, 209, 330-337.	0.4	18
92	[12] Biosynthesis of bis(monoacylglycero)phosphate in liver and macrophage lysosomes. Methods in Enzymology, 1992, 209, 104-110.	0.4	3
93	Lipid conjugates of antiretroviral agents: Release of antiretroviral nucleoside monophosphates by a nucleoside diphosphate diglyceride hydrolase activity from rat liver mitochondria. Lipids and Lipid Metabolism, 1991, 1084, 307-310.	2.6	35
94	Effect of thyroxine on the activity of mitochondrial cardiolipin synthase in rat liver. Lipids and Lipid Metabolism, 1991, 1086, 139-140.	2.6	65
95	Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo. Biochemical Pharmacology, 1991, 41, 1007-1013.	2.0	14
96	[29] Purification of rat kidney lysosomal phospholipase A1. Methods in Enzymology, 1991, 197, 325-330.	0.4	4
97	[11] Assay of phospholipases C and D in presence of other lipid hydrolases. Methods in Enzymology, 1991, 197, 125-134.	0.4	15
98	Role of phospholipases in myocardial ischemia: effect of cardioprotective agents on the phospholipases A of heart cytosol and sarcoplasmic reticulum in vitro. Molecular and Cellular Biochemistry, 1989, 88, 77-82.	1.4	11
99	Inhibition of purified human postheparin lipoprotein lipase by beta-adrenergic blockers in vitro. Biochemical Pharmacology, 1989, 38, 407-411.	2.0	7
100	Role of phospholipases in myocardial ischemia: effect of cardioprotective agents on the phospholipases A of heart cytosol and sarcoplasmic reticulum in vitro., 1989,, 77-82.		0
101	In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. Lipids and Lipid Metabolism, 1988, 959, 316-321.	2.6	58
102	Propranolol inhibition of the neutral phospholipases a of rat heart mitochondria, sarcoplasmic reticulum and cytosol. Biochemical Pharmacology, 1987, 36, 4251-4256.	2.0	21
103	Inhibition of purified bovine milk lipoprotein lipase by propranolol and other \hat{l}^2 -adrenergic blockers in vitro. Lipids and Lipid Metabolism, 1987, 918, 168-174.	2.6	10
104	Role of phospholipase A inhibition in amiodarone pulmonary toxicity in rats. Lipids and Lipid Metabolism, 1986, 875, 400-405.	2.6	78
105	Binding of propranolol and gentamicin to small unimellar phospholipid vesicles. Biochemical Pharmacology, 1986, 35, 3761-3765.	2.0	41
106	Fate of influenza a virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine. Virology, 1986, 151, 200-210.	1.1	29
107	Purification of lysosomal phospholipase A and demonstration of proteins that inhibit phospholipase A in a lysosomal fraction from rat kidney cortex. Biochemistry, 1986, 25, 6456-6461.	1.2	24
108	Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. Biochemistry, 1985, 24, 6515-6520.	1,2	80

7

#	Article	IF	Citations
109	Diethylaminoethoxyhexestrol causes hypertriglyceridemia in guinea pigs. Lipids and Lipid Metabolism, 1985, 833, 165-169.	2.6	1
110	Inhibition of purified lysosomal phospholipase A1 by beta-adrenoceptor blockers. Biochemical Pharmacology, 1985, 34, 521-524.	2.0	36
111	Liposome Entrapment Enhances the Hypocalcemic Action of Parenterally Administered Calcitonin*. Endocrinology, 1984, 115, 757-761.	1.4	19
112	Chloroquine treatment does not cause phospholipid storage by depleting rat liver lysosomes of acid phospholipase a. Lipids and Lipid Metabolism, 1984, 793, 497-501.	2.6	9
113	Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochemical Pharmacology, 1984, 33, 1639-1644.	2.0	46
114	Chapter 6 Polyglycerophospholipids: phosphatidylglycerol, diphosphatidylglycerol and bis (monoacylglycero) phosphate. New Comprehensive Biochemistry, 1982, 4, 215-261.	0.1	19
115	Studies on the mechanism of phospholipid storage induced by amantadine and chloroquine in Madin Darby canine kidney cells. Biochemical Pharmacology, 1982, 31, 3795-3799.	2.0	48
116	Aminoglycoside antibiotics inhibit lysosomal phospholipase A and C from rat liver in vitro. Lipids and Lipid Metabolism, 1982, 710, 506-509.	2.6	29
117	Studies on the mechanism of drug-induced lipidosis. Biochemical Pharmacology, 1981, 30, 1121-1126.	2.0	106
118	The intracellular distribution and antiviral activity of amantadine. Virology, 1981, 112, 81-90.	1.1	42
119	Deficiency of carnitine palmitoyltransferase in transformed lymphoblasts from a patient having a deficiency of carnitine palmitoyltransferase in skeletal muscle. Biochemical and Biophysical Research Communications, 1980, 94, 270-277.	1.0	6
120	Phospholipid transfer activities in morris hepatomas and the specific contribution of the phosphatidylcholine exchange protein. Biochimica Et Biophysica Acta - Biomembranes, 1980, 600, 376-386.	1.4	61
121	Effects of chloroquine and 4,4'-bis(diethylaminoethoxy) \hat{l}_{\pm} , \hat{l}_{\pm} -diethyldiphenylethane on the incorporation of [3H]glycerol into the phospholipids of rat liver lysosomes and other subcellular fractions, in vivo. Lipids and Lipid Metabolism, 1980, 620, 592-602.	2.6	28
122	Phospholipase C activity of rat tissues. Biochemical and Biophysical Research Communications, 1980, 96, 388-393.	1.0	72
123	CARNITINE AND CARNITINE PALMITOYLTRANSFERASE IN METABOLIC STUDIES. , 1980, , 287-305.		11
124	Partial Deficiency of Muscle Carnitine Palmitoyltransferase with Normal Ketone Production. New England Journal of Medicine, 1978, 298, 553-557.	13.9	63
125	ACIDIC PHOSPHOLIPIDS AND LYSOSOMAL BIS (MONOACYLGLYCERYL) PHOSPHATE SYNTHESIS: THE ROLE OF PHOSPHATIDYLINOSITOL AND LYSOPHOSPHATIDYLGLYCEROL. , 1978, , 585-597.		1
126	Increased mitochondrial CTP: Phosphatidic acid cytidyltransferase in the 7777 hepatoma. Biochemical and Biophysical Research Communications, 1976, 72, 418-425.	1.0	8

#	Article	IF	CITATIONS
127	Abnormal membrane phospholipid content in subcellular fractions from the morris 7777 hepatoma. Lipids and Lipid Metabolism, 1976, 441, 231-238.	2.6	49
128	Studies on nucleotide diphosphate diacylglycerol specificity of acidic phospholipid biosynthesis in rat liver subcellular fractions. Lipids and Lipid Metabolism, 1976, 431, 408-415.	2.6	18
129	Further studies on the formation of cardiolipin and phosphatidylglycerol in rat liver mitochondria. Lipids and Lipid Metabolism, 1975, 380, 382-389.	2.6	82
130	Biosynthesis of cardiolipin in liver mitochondria. Lipids and Lipid Metabolism, 1971, 239, 113-119.	2.6	126
131	Effect of L-Epinephrine and Triamcinolone on the Incorporation of Acetate-2- ¹⁴ C and ³² Pi Into Phospholipids and Neutral Lipids in Liver Slices from Adrenalectomized Rats, <i>in Vitro</i>	1.4	1
132	Estimation of the Pentose Cycle Contribution to Glucose Metabolism in Tissue in Vivo*. Biochemistry, 1967, 6, 2961-2964.	1.2	108